NewslettersPancreatic Cell NewsUncategorizedTrevena Announces Advancement of TRV045 Into Clinical Development for Diabetic Neuropathic PainBy Justin.choi - December 14, 2021031Trevena, Inc. announced it is advancing TRV045 into clinical development, following receipt of a notification from the US FDA that the study may proceed.[Trevena, Inc.] 6445212 nan items 1 apa 0 default asc 1 170050 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Press Release